HELICASE PRIMASE INHIBITORS FOR TREATING CANCER IN A COMBINATION THERAPY WITH ONCOLYTIC VIRUSES

(19)

(11)

EP 3 886 847 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.10.2024 Bulletin 2024/40

(45)	Mention of the grant of the patent:
	21.08.2024 Bulletin 2024/34

(21)	Application number: 19808606.8

(22)	Date of filing: 27.11.2019

(51)

International Patent Classification (IPC):

A61K 31/4245^(2006.01)
A61K 31/426^(2006.01)
A61K 45/06^(2006.01)
A61K 39/12^(2006.01)
C12N 7/00^(2006.01)

A61K 31/4439^(2006.01)
A61K 35/763^(2015.01)
A61P 35/00^(2006.01)
A61P 31/22^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/4245; A61K 31/426; A61K 31/4439; A61K 39/12; A61K 45/06; A61P 31/22; A61P 35/00; C12N 7/00; C12N 2710/16632; C12N 2710/16634

	C-Sets:
	A61K 35/763, A61K 2300/00; A61K 31/4245, A61K 2300/00; A61K 31/4439, A61K 2300/00; A61K 31/426, A61K 2300/00;

(86)	International application number:
	PCT/EP2019/082751

(87)	International publication number:
	WO 2020/109389 (04.06.2020 Gazette 2020/23)

(54)

HELICASE PRIMASE INHIBITORS FOR TREATING CANCER IN A COMBINATION THERAPY WITH ONCOLYTIC VIRUSES

HELIKASE-PRIMASE-INHIBITOREN ZUR BEHANDLUNG VON KREBS IN EINER KOMBINATIONSTHERAPIE MIT ONKOLYTISCHE VIREN

INHIBITEURS D'HÉLICASE-PRIMASE POUR LE TRAITEMENT DU CANCER DANS UNE THÉRAPIE COMBINÉE AVEC DES VIRUS ONCOLYTIQUES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

28.11.2018 EP 18208756

(43)	Date of publication of application:
	06.10.2021 Bulletin 2021/40

(73)	Proprietor: Innovative Molecules GmbH
	81373 München (DE)

(72)	Inventors:
	KLEYMANN, Gerald 32107 Bad Salzuflen (DE) GEGE, Christian 89584 Ehingen (DE)

(74)	Representative: Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte
	Brucknerstraße 20 40593 Düsseldorf 40593 Düsseldorf (DE)

(56)

References cited: :

WO-A1-2017/174640

D KOLODKIN-GAL ET AL: "Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect", GENE THERAPY, vol. 16, no. 7, 14 May 2009 (2009-05-14), GB, pages 905 - 915, XP055589479, ISSN: 0969-7128, DOI: 10.1038/gt.2009.44
YAJIMA MISAKO ET AL: "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 139, 24 December 2016 (2016-12-24), pages 95 - 101, XP029901946, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2016.12.008
QUENELLE DEBRA C ET AL: "Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis", ANTIVIRAL RESEARCH, vol. 149, 4 November 2017 (2017-11-04), pages 1 - 6, XP085315572, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2017.11.002

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).